AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump

AstraZeneca broke ground on a $4.5 billion plant in Virginia, responding to President Trumps push for increased domestic medicine production at lower costs.

• On October 9, AstraZeneca announced the groundbreaking of a new facility in Virginia, marking a significant investment of $4.5 billion in U.S. manufacturing.
• The new Virginia plant aims to bolster domestic drug production, aligning with President Trumps emphasis on reducing pharmaceutical costs and increasing local manufacturing.
• This major investment from AstraZeneca comes amid broader efforts by drugmakers to expand U.S. operations and address supply chain vulnerabilities exposed during the pandemic.